97-10201. Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Recombinant F1-V Plague Vaccine

[Federal Register Volume 62, Number 76 (Monday, April 21, 1997)]
[Notices]
[Page 19314]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-10201]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability of Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Recombinant F1-V Plague 
Vaccine

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 38 CFR 404.6, announcement is made of the 
availability of U.S. Patent Application SN 08/699,716 entitled 
``Recombinant F1-V Plague Vaccine,'' filed December 18, 1996. This 
patent has been assigned to the United States Government as represented 
by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
Command Judge Advocate, ATTN: MCMR-JA, 504 Scott Street, Fort Detrick, 
MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney, 
301-619-7807, Fax [phone].

SUPPLEMENTARY INFORMATION: A recombinant plague vaccine (F1-V) based on 
a fusion protein composed of the entire capsule protein (F1) and V 
protein of Yersinia pestis has been developed. Initial preclinical 
studies in mice have shown this fusion protein when combined with an 
adjuvant to be efficicacious against fully virulent wild-type and F-1 
strains of Yersinia pestis. The vaccine has been tested against both 
subcutaneous and aerosol challenges, which should mimic the bubonic and 
pneumonic form of plague. This F1-V vaccine has been shown to be 
superior to the licensed, whole cell, Plague Vaccine USP in a mouse 
model. It also offers the advantage of being a defined product which 
may be less reactogenic than the poorly defined whole cell vaccine. The 
use of fusion protein offfers advantages of producing and purifying a 
single protein, instead of two separate components, which may result in 
lower manufacturing costs.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 97-10201 Filed 4-18-97; 8:45 am]
BILLING CODE 3710-08-M